Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Mkt Cap: US$87.5b

We’ve recently updated our valuation analysis.

Regeneron Pharmaceuticals Valuation

Is REGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGN?

Other financial metrics that can be useful for relative valuation.

REGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.2x
Enterprise Value/EBITDA14.2x
PEG Ratio4.6x

Price to Earnings Ratio vs Peers

How does REGN's PE Ratio compare to its peers?

The above table shows the PE ratio for REGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average28.3x
VRTX Vertex Pharmaceuticals
24.3x9.2%US$80.8b
GILD Gilead Sciences
21.8x8.4%US$99.9b
AMGN Amgen
19.4x3.9%US$127.1b
HZNP Horizon Therapeutics
47.5x20.2%US$24.8b
REGN Regeneron Pharmaceuticals
20.2x4.4%US$87.5b


Price to Earnings Ratio vs Industry

How does REGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.5%
n/an/an/a
No more companies


Price to Earnings Ratio vs Fair Ratio

What is REGN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.2x
Fair PE Ratio23.7x

Price-To-Earnings vs Fair Ratio: REGN is good value based on its Price-To-Earnings Ratio (20.2x) compared to the estimated Fair Price-To-Earnings Ratio (23.7x).


Share Price vs Fair Value

What is the Fair Price of REGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$820.00
US$860.87
+5.0%
11.1%US$1,040.00US$605.00n/a23
Mar ’24US$770.44
US$830.78
+7.8%
12.2%US$1,011.00US$605.00n/a23
Feb ’24US$758.00
US$800.94
+5.7%
12.8%US$1,023.00US$605.00n/a24
Jan ’24US$721.49
US$801.04
+11.0%
13.0%US$1,027.00US$595.00n/a23
Dec ’23US$761.24
US$795.83
+4.5%
13.3%US$1,027.00US$575.00n/a23
Nov ’23US$759.91
US$780.78
+2.7%
13.4%US$1,025.00US$575.00n/a23
Oct ’23US$688.87
US$749.00
+8.7%
11.2%US$925.00US$575.00n/a22
Sep ’23US$600.63
US$676.32
+12.6%
10.7%US$796.00US$536.00n/a22
Aug ’23US$576.68
US$674.05
+16.9%
10.5%US$790.00US$536.00n/a22
Jul ’23US$595.40
US$679.24
+14.1%
11.5%US$790.00US$536.00n/a21
Jun ’23US$658.92
US$691.67
+5.0%
9.3%US$790.00US$565.00n/a21
May ’23US$659.11
US$685.40
+4.0%
10.4%US$781.00US$565.00n/a20
Apr ’23US$694.83
US$689.71
-0.7%
11.2%US$843.00US$570.00n/a21
Mar ’23US$607.03
US$691.91
+14.0%
11.3%US$843.00US$560.00US$770.4422
Feb ’23US$613.36
US$695.55
+13.4%
12.4%US$843.00US$555.00US$758.0022
Jan ’23US$631.52
US$707.91
+12.1%
12.0%US$850.00US$570.00US$721.4923
Dec ’22US$630.59
US$697.52
+10.6%
12.6%US$850.00US$565.00US$761.2421
Nov ’22US$639.15
US$683.91
+7.0%
12.2%US$842.00US$555.00US$759.9122
Oct ’22US$570.79
US$682.77
+19.6%
12.0%US$831.00US$545.00US$688.8722
Sep ’22US$680.96
US$675.82
-0.8%
13.6%US$906.00US$540.00US$600.6322
Aug ’22US$574.61
US$635.39
+10.6%
13.7%US$828.00US$460.00US$576.6823
Jul ’22US$574.62
US$625.17
+8.8%
13.3%US$814.00US$460.00US$595.4023
Jun ’22US$503.23
US$621.18
+23.4%
13.6%US$814.00US$460.00US$658.9222
May ’22US$481.30
US$625.64
+30.0%
12.4%US$794.00US$477.00US$659.1122
Apr ’22US$474.93
US$636.38
+34.0%
12.0%US$795.00US$500.00US$694.8324
Mar ’22US$463.05
US$635.67
+37.3%
12.0%US$795.00US$500.00US$607.0324


Discover undervalued companies